GlassScriptPhysician profile
Matthew Riesbeck
NPI 1154701696
$12,622.02
in general payments reported to CMS, 2019-2025
33 companies · $3,575 in 2025
The $3,575 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $533 · 2021: $1,159 · 2022: $2,259 · 2023: $2,370 · 2024: $2,265 · 2025: $3,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,110 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,109.93 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,824.90 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Navitor |
| Actelion Pharmaceuticals US, INC. | $927.32 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $643.77 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $578.43 | 2022-2024 | Optimizer, Optimizer |
| United Therapeutics Corporation | $451.61 | 2022-2025 | Tyvaso, Tyvaso, Remodulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $435.70 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $393.43 | 2023-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $330.75 | 2022-2025 | Winrevair, Verquvo |
| Biotronik INC. | $317.42 | 2021 | |
| Bard Peripheral Vascular, INC. | $290.00 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $289.39 | 2022-2025 | |
| Cvrx, INC. | $230.17 | 2024-2025 | Barostim Neo System |
| Boston Scientific Corporation | $224.16 | 2020-2021 | |
| Pfizer INC. | $212.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $206.17 | 2024-2025 | Camzyos, Eliquis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $163.28 | 2022-2024 | |
| Bridgebio Pharma, INC. | $158.77 | 2025 | Attruby |
| Zoll Respicardia, INC. | $142.22 | 2021 | |
| Abiomed | $129.45 | 2022 | |
| Siemens Medical Solutions USA, INC. | $120.11 | 2020 | |
| Janssen Pharmaceuticals, INC | $96.60 | 2022-2024 | Xarelto |
| Philips North America LLC | $89.58 | 2019 | |
| Amgen INC. | $72.42 | 2022-2023 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $51.36 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $47.74 | 2023 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Sanofi-Aventis U.S. LLC | $46.19 | 2022 | |
| Alnylam Pharmaceuticals INC. | $31.45 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $26.50 | 2024 | |
| Novo Nordisk INC | $19.62 | 2024 | Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $18.68 | 2023 | Arcalyst |
| Shockwave Medical, INC | $18.66 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.25 | 2019 | |
| Chiesi USA, INC. | $16.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Riesbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.